Dr. Glen Markowitz, M.D

NPI: 1457488736
Total Payments
$5,657
2024 Payments
$58.61
Companies
3
Transactions
7
Medicare Patients
182
Medicare Billing
$13,638

Payment Breakdown by Category

Consulting$4,950 (87.5%)
Research$542.30 (9.6%)
Food & Beverage$164.97 (2.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $4,950 2 87.5%
Unspecified $542.30 2 9.6%
Food and Beverage $164.97 3 2.9%

Payments by Type

General
$5,115
5 transactions
Research
$542.30
2 transactions

Top Paying Companies

Company Total Records Latest Year
GENZYME CORPORATION $5,492 4 $0 (2019)
Novartis Pharmaceuticals Corporation $133.60 2 $0 (2024)
Alexion Pharmaceuticals, Inc. $31.37 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2024 $58.61 1 Novartis Pharmaceuticals Corporation ($58.61)
2023 $74.99 1 NOVARTIS PHARMACEUTICALS CORPORATION ($74.99)
2019 $224.40 1 GENZYME CORPORATION ($224.40)
2018 $317.90 1 GENZYME CORPORATION ($317.90)
2017 $4,981 3 GENZYME CORPORATION ($4,950)

All Payment Transactions

7 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
09/27/2024 Novartis Pharmaceuticals Corporation Fabhalta (Drug) Food and Beverage In-kind items and services $58.61 General
Category: Immunology
11/03/2023 NOVARTIS PHARMACEUTICALS CORPORATION Food and Beverage In-kind items and services $74.99 General
03/05/2019 GENZYME CORPORATION LEMTRADA (Drug) In-kind items and services $224.40 Research
Study: A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study • Category: MULTIPLE SCLEROSIS
11/28/2018 GENZYME CORPORATION LEMTRADA (Drug) In-kind items and services $317.90 Research
Study: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) • Category: MULTIPLE SCLEROSIS
04/05/2017 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Consulting Fee Cash or cash equivalent $2,475.00 General
04/04/2017 GENZYME CORPORATION LEMTRADA (Drug) Consulting Fee Cash or cash equivalent $2,475.00 General
Category: MULTIPLE SCLEROSIS
03/05/2017 Alexion Pharmaceuticals, Inc. SOLIRIS (Drug) Food and Beverage In-kind items and services $31.37 General
Category: Immunology

Research Studies & Clinical Trials

Study Name Company Amount Records
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) GENZYME CORPORATION $317.90 1
A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study GENZYME CORPORATION $224.40 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 121 323 $50,984 $8,388
2022 5 61 160 $30,914 $5,250
Total Patients
182
Total Services
483
Medicare Billing
$13,638
Procedure Codes
10

All Medicare Procedures & Services

10 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
88350 Antibody evaluation, each additional single antibody stain procedure Facility 2023 25 174 $22,620 $4,393 19.4%
88348 Electron microscopy for diagnosis Facility 2023 23 24 $13,694 $1,543 11.3%
88305 Pathology examination of tissue using a microscope, intermediate complexity Facility 2023 24 26 $4,680 $843.44 18.0%
88346 Antibody evaluation, initial single antibody stain procedure Facility 2023 25 27 $5,670 $842.13 14.9%
88313 Special stained specimen slides to examine tissue including interpretation and report Facility 2023 24 72 $4,320 $766.80 17.8%
88350 Antibody evaluation, each additional single antibody stain procedure Office 2022 13 90 $13,300 $3,002 22.6%
88348 Electron microscopy for diagnosis Office 2022 12 12 $9,364 $736.07 7.9%
88313 Special stained specimen slides to examine tissue including interpretation and report Office 2022 11 33 $2,730 $560.05 20.5%
88346 Antibody evaluation, initial single antibody stain procedure Office 2022 13 13 $3,040 $525.16 17.3%
88305 Pathology examination of tissue using a microscope, intermediate complexity Office 2022 12 12 $2,480 $426.93 17.2%

About Dr. Glen Markowitz, M.D

Dr. Glen Markowitz, M.D is a Anatomic Pathology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1457488736.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Glen Markowitz, M.D has received a total of $5,657 in payments from pharmaceutical and medical device companies, with $58.61 received in 2024. These payments were reported across 7 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($4,950).

As a Medicare-enrolled provider, Markowitz has provided services to 182 Medicare beneficiaries, totaling 483 services with total Medicare billing of $13,638. Data is available for 2 years (2022–2023), covering 10 distinct procedure/service records.

Practice Information

  • Specialty Anatomic Pathology
  • Location New York, NY
  • Active Since 02/27/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 207ZP0101X
  • Entity Type Individual
  • NPI Number 1457488736

Products in Payments

  • LEMTRADA (Drug) $3,017
  • NO PRODUCT DISCUSSED (Drug) $2,475
  • Fabhalta (Drug) $58.61
  • SOLIRIS (Drug) $31.37

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Anatomic Pathology Doctors in New York